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163* Lung disease progression in children with cystic ﬁbrosis
S.W. Terheggen/Lagro, H.G. Arets, C.K. van der Ent. University Medical Centre
Utrecht, Utrecht, Netherlands
Chronic airway infection and inﬂammation in cystic ﬁbrosis (CF) lung disease
lead to structural lung damage, pulmonary dysfunction and eventually respiratory
insufﬁciency.
We evaluated airway disease progression assessed by radiology, expiratory inter-
rupter resistance (Rintexp), and spirometry in young children with CF over a 3-year
interval.
Two chest radiographs combined with two Rintexp measurements were performed
in 21 preschool children (mean (SD) age 3.2 (0.9) years) and 30 school children
(mean (SD) age 7.2 (1.9) years) with CF. Chest radiographs were scored using
ﬁve different CF scoring systems i.e. the Chrispin–Norman, adjusted Chrispin–
Norman, Wisconsin, Northern and Brasﬁeld scoring system by two observers.
Rintexp measurements were expressed as height adjusted Z-scores. Spirometry was
assessed in school children and results were expressed as percent predicted.
Chest radiograph scores worsened signiﬁcantly over the 3 year period and worsening
was most prominent in preschool children. Most preschool and school children had
Rintexp Z-scores within the normal range at start and follow-up, and annual change
in Rintexp Z-score was not signiﬁcant. In school children only forced expiratory
volume in 1 second as percentage of forced vital capacity (FEV1%FVC) declined
signiﬁcantly during the study period.
In young children with CF, chest radiograph scores worsen signiﬁcantly over time
while lung function remains stable.
Supported by: Netherlands Organization for Health Research and Development
(ZonMW).
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Chronic pulmonary colonisation with Pseudomonas aeruginosa in patients with
cystic ﬁbrosis is associated with a high morbidity and mortality.
Objective: to determine the prevalence of acquiring Pseudomonas aeruginosa
during early chilhood in patients with cystic ﬁbrosis.
Method: retrospective cohort study of 75 children with cyctic ﬁbrosis identiﬁed by
newborn screening during 1985–2005. 47 patients/75 had a clinical, bacteriological
regular follow-up in our center during 20 years. The Kaplan-Meier estimator was
used to assess differences in Pseudomonas free survival time between period 1
(1985–1995) and period 2 (1995–2005).
Results: 11% of patients acquired Pseudomonas aeruginosa in the ﬁrst 6 months
of life, 30% to 3 years, 48% to 7 years and 85% to 18 years without signiﬁcant
difference according to the sex (p = 0.9). The ﬁrst colonisation with Pseudomonas
aeruginosa signiﬁcantly appears earlier during period 2 compared with period 1.
53% of patients acquired Pseudomonas aeruginosa at the 3 years age during
period 2 against 9% during period 1.
Conclusion: the age of ﬁrst colonisation with Pseudomonas aeruginosa becomes
increasingly early in our center. It appears important to take measures and to set
up the program of anti-Pseudomonas vaccination in order to as much as possible
delay the age of the ﬁrst colonisation with Pseudomonas aeruginosa.
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Introduction: MBL is a circulating plasma protein that plays a pivotal role in the
innate immunity by different mechanisms. MBL deﬁciency arising from mutations
and promoter polymorphisms in the mbl2 gene has been proposed to modulate
disease severity in patients with CF.
Objectives: To investigate whether MBL2 structural variants are associated with
disease severity and survival in CF patients.
Methods: We retrospectively study children with diagnosis of CF with two severe
mutations in the CF gene. Pulmonary involvement was deﬁned according to clinical
data and pulmonary functional test. MBL genotypes were assessed by PCR-RFLP
and based on the presence of structural and promoter alleles MBL sufﬁciency
(AA/YY or AA/XY alleles) and MBL insufﬁciency groups (A/O, O/O or AA/XX
alleles) were deﬁned.
Results: We studied 38 patients with CF and 132 controls from the blood bank
of the hospital. There were no signiﬁcant differences related to the frequencies of
the mbl2 gene between CF and healthy controls. In the CF population, 27 subjects
had MBL sufﬁciency and 11 were MBL insufﬁcient. Nine of 11 developed a severe
pulmonary involvement (p = 0.07 OR 5.625 95%CI 1.01−31.1) and 7 of 11 died at
the moment of the study.
Conclusions:MBL insufﬁciency may play a role in the severity of lung involvement
and survival in CF patients
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Background: CF patients have worsening lung function over time due to persistent
infection, and underlying inﬂammation. Azithromycin (AZ) given three times
weekly to CF patients colonized with Pseudomonas aeruginosa (PA) has been
shown to improve lung function and reduce exacerbations.
Objective: To determine if the beneﬁt of AZ in adults with CF is affected by
gender, diabetes & severity of pulmonary disease (mild, moderate & severe).
Method: A retrospective casenotes review of patients colonized with PA who had
been prescribed AZ (500mg 3 times weekly) for at least six months. Data collected
included forced expiratory volume at one second (FEV1) & body mass index (BMI);
values were obtained from outpatient visits 6 months before, at treatment initiation,
and 6 months after treatment was commenced. Patients not colonized with PA were
excluded as they were not routinely given AZ.
Results: 114 case-notes were reviewed. 46 patients (40%) were given AZ. 24 pa-
tients (21%) were not colonized with PA & were not given AZ. A further 27 patients
(24%) were not compliant with therapy; their data was not included. Data was not
available for 17 patients (15%). As expected, FEV1 fell in all patients over the
6 months prior to starting AZ (mean fall 0.01±0.27%). Patients with diabetes had
a statistically signiﬁcant increase in FEV1 after 6 months therapy with AZ (p = 0.03).
There was a trend to an increase in BMI in the diabetics (p = 0.09). Neither gender,
nor severity of lung disease affected the response to AZ.
Conclusions: In patients with CF who are chronically colonized with PA, those
who have CF related diabetes show more improvement in FEV1 and a trend to
improvement in BMI. In our patients’ gender and severity of lung disease does not
affect the response to AZ.
